Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival

ELISABETTA Gambale; VALERIA EMMA Palmieri; VIRGINIA Rossi; EDOARDO Francini; ADELE Bonato; ALESSIA Salfi; LUCA Galli; MARINELLA MICOL Mela; SERENA Pillozzi; LORENZO Antonuzzo

doi:10.21873/cdp.10252

Back

Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival

Journal article

Open access

Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival

ELISABETTA Gambale, VALERIA EMMA Palmieri, VIRGINIA Rossi, EDOARDO Francini, ADELE Bonato, ALESSIA Salfi, LUCA Galli, MARINELLA MICOL Mela, SERENA Pillozzi and LORENZO Antonuzzo

Cancer diagnosis & prognosis, Vol.3(5), pp.538-542

09/01/2023

DOI: 10.21873/cdp.10252

PMCID: PMC10475921

PMID: 37671314

Files and links (1)

url

https://doi.org/10.21873/cdp.10252View

Published (Version of record) Open Access

Abstract

Background/aim: We performed a multicenter retrospective observational study to investigate the impact of immune checkpoint inhibitors (ICIs) on the survival of patients with bone metastases (BMs) from renal cell cancer (RCC). Patients and methods: A total of 98 patients with metastatic RCC (mRCC) treated with ICIs were retrospectively enrolled. All patients received standard treatments with nivolumab alone or in combination with ipilimumab from December 2015 to March 2022. The primary endpoint was median overall survival (OS). Results: Forty-three patients (44%) had radiological evidence of BMs. No statistically significant difference in OS was reported between the BM population and the entire population (p=0.254). Conclusion: Our study suggests some degree of ICI activity to treat patients with BMs from RCC, historically associated with a poorer prognosis.

Immunotherapy

bone metastases

overall survival

renal cell cancer

Details

Title: Subtitle: Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival
Creators: ELISABETTA Gambale - Azienda Ospedaliero-Universitaria Careggi
VALERIA EMMA Palmieri - Hospital of Prato
VIRGINIA Rossi - Azienda Ospedaliero-Universitaria Careggi
EDOARDO Francini - University of Florence
ADELE Bonato - Azienda Ospedaliera Universitaria Pisana
ALESSIA Salfi - Azienda Ospedaliera Universitaria Pisana
LUCA Galli - Azienda Ospedaliera Universitaria Pisana
MARINELLA MICOL Mela - Azienda Ospedaliero-Universitaria Careggi
SERENA Pillozzi - Azienda Ospedaliero-Universitaria Careggi
LORENZO Antonuzzo - Azienda Ospedaliero-Universitaria Careggi
Resource Type: Journal article
Publication Details: Cancer diagnosis & prognosis, Vol.3(5), pp.538-542
DOI: 10.21873/cdp.10252
PMID: 37671314
PMCID: PMC10475921
NLM abbreviation: Cancer Diagn Progn
ISSN: 2732-7787
eISSN: 2732-7787
Publisher: International Institute of Anticancer Research
Number of pages: 5
Language: English
Date published: 09/01/2023
Academic Unit: Internal Medicine
Record Identifier: 9985221246702771

Metrics

1 Record Views